Blue Cross and Blue Shield of New Mexico (BCBSNM) is closely monitoring activity around the Novel Coronavirus 2019 (COVID-19). We've taken steps to help lower costs and provide our members easier access to care related to COVID-19.
Testing and Treatment Coverage
During the public health emergency (PHE), we are covering FDA-authorized testing to diagnose COVID-19 for our members with no prior authorization needed. COVID-19 tests are covered with no member copays, deductibles or co-insurance when an individual’s health care provider determines that it is medically appropriate to treat or diagnose COVID-19. Testing coverage include tests for pneumonia and influenza with no member cost share. We also cover testing-related visits with in-network providers with no member copays, deductibles or coinsurance. For fully-insured and IBAC members, and pursuant to the OSI cost share waiver rule, cost share is waived for COVID-19-related testing.
Over-the-Counter (OTC) Tests: We cover COVID-19 diagnostic tests members buy without a provider’s involvement or prescription, starting Jan. 15, 2022, through the end of the federal public health emergency. OTC tests must be FDA-authorized. This applies to fully insured, self-insured and individual and family plans. Members can buy up to eight tests per covered member every 30 days. This program is through BCBSIL and Prime TherapeuticsTM pharmacy benefits. If a member does not have benefits through Prime Therapeutics, they should contact their pharmacy benefit administrator. More information is on our member microsite.
For treatment of COVID-19, we temporarily waived member cost-sharing, including copays, deductibles and coinsurance for the following members through Dec. 31, 2020:
- Fully insured employer-based (cost share waiver not limited to in-network)
- Interagency Benefits Advisory Council (IBAC) (cost share waiver not limited to in-network)
- Medicare (no se incluye la Parte D)
- Medicare Supplement members
- Medicaid members
For fully insured and IBAC members, the cost-share waiver that began on March 12, 2020, remains in effect. Fully insured and IBAC members will not pay copays, deductibles or coinsurance for COVID-19 testing or treatment. This OSI cost share waiver rule currently has no end date.
Follow our “Cobertura para el COVID-19 para asegurados” web page for updates.
Note on self-insured groups: Many of our members are covered under a health plan that is self-insured by their employer. Some of these members may have cost-share waived for treatment of COVID-19 depending on their employer’s decision about its benefit plan.
Some members may not have access to out-of-network benefits. In addition, if members receive treatment at out-of-network providers, any cost-share waiver does not protect a member from provider balance or surprise billing. Members may be subject to balance or surprise billing depending on their benefit terms and state or federal laws since a provider may not accept the amount covered under the benefit plan as payment in full.
Medicare members: Medicare (excluding Part D) and Medicare Supplement members won't pay copays, deductibles or coinsurance for:
- Medically necessary lab tests to diagnose COVID-19 that are consistent with CDC guidance
- Testing-related visits related to COVID-19 with in-network providers, including at a provider's office, urgent care clinic, emergency room and by telehealth
Blue Cross Group Medicare SupplementSM and Blue Cross Medicare SupplementSM members do not have network restrictions unless otherwise noted on their plans.
Members should always call the number on their ID card for answers to their specific benefit questions. Vea nuestras FAQs for Medicare Providers para ver más detalles.
Check Member Eligibility and Benefits
Use la Availity® Provider Portal 
or your preferred vendor for eligibility and benefit verifications.
Vacuna contra el COVID-19
For information about our COVID-19 vaccination policy, see our News & Update article.
Claims for COVID-19 Testing
If you are collecting a COVID sample from a member, have a lab capable of testing, or are a lab testing a member, submit the claim using the appropriate collection or lab code. Member cost-share for the test will be waived during the public health emergency (PHE) declared by the Secretary of the Department of Health and Human Services. Testing must be:
- For individualized diagnosis or treatment of COVID-19
- Medically appropriate
- In accordance with generally accepted standards of care, including the Centers for Disease Control (CDC) guidance
For more detail on COVID-19 coding and guidance, refer to the American Medical Association |
COVID-19 Collection Codes
For details about the collection codes, see CMS' Frequently Asked Questions (FAQs) on Medicare Fee-for-Service Billing
Codes |
Descripción |
|---|---|
C9803 |
For use by hospital outpatient departments: Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) any specimen source |
G2023 |
For use by independent clinical diagnostic labs: Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
G2024 |
For use by independent clinical diagnostic labs: Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a SNF or by a laboratory on behalf of a HHA, any specimen source |
COVID-19 Lab Codes
Codes |
Descripción |
|---|---|
0202U |
Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR |
0223U |
Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected |
0225U |
Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected |
0226U |
Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), ELISA, plasma, serum |
0240U |
Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected |
0241U |
Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected |
87426 |
Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) |
87428 |
Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B |
87635 |
Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique |
87636 |
Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique |
87637 |
Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique |
87811 |
Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) |
U0001 |
CDC 2019 Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel |
U0002 |
2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC |
U0003 |
Infectious agent detection by nucleic acid (DNA or RNA); Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R |
U0004 |
2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R |
U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection |
COVID-19 Testing Before Non-COVID-19 Treatment or Procedures
When screening for COVID-19 before elective procedures or treatment not related to COVID-19 active disease or suspicion, bill the test on a separate claim from the rest of the services being rendered. By doing this, our members receive the cost-share waiver for COVID testing and the claim will be processed promptly. The appropriate benefits will apply to the remainder of each member’s non-COVID related care.
Pruebas para hacer en el hogar
We cover at-home collection methods for COVID-19 testing if the tests are FDA-authorized and are clinically indicated for the member as determined by the member's health care provider. We encourage members to consult with their health care provider to determine whether the test is medically appropriate for their condition. Medical or invoice records may be requested to support if an antibody test is FDA authorized or if EUA approval has been requested.
Emergency Room COVID-19 Testing with No Presenting Symptoms
Testing for COVID-19 should be for individualized treatment or diagnosis. If testing is used to screen for COVID-19 before emergency room services not related to COVID-19 active disease or suspicion, bill the test on a separate claim from the rest of the services being rendered. By doing this, we will be able to identify when members should receive the cost-share waiver for COVID-19 testing, and the claim will be processed promptly. The remainder of each member’s non-COVID-19 related emergency room care will be processed according to the member’s benefit plan.
Claims for COVID-19 Antibody Testing
Submit claims for COVID-19 antibody testing to us using the appropriate code. Member cost-share (copay, deductibles and coinsurance) will be waived for antibody tests that are FDA authorized, including tests with Emergency Use Authorized (EUA), regardless of the diagnosis. This waiver will last through the end of the PHE. Medical or invoice records may be requested to support if an antibody test is FDA authorized or if EUA approval has been requested.
Antibody Testing Requirements
Antibody tests must be FDA-authorized, including EUA. Antibody testing should be medically appropriate for the member and ordered by a health care provider. We encourage members to consult with their health care provider to determine the best, medically appropriate test for their condition. Refer to the current FDA position on antibody testing . Medical or invoice records may be requested to support if an antibody test is FDA authorized or if EUA approval has been requested.
Código |
Descripción |
|---|---|
0224U |
Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed |
86318 |
Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method |
86328 |
Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method, severe acute respiratory syndrome coronavirus (SARS-CoV-2) (Coronavirus disease COVID-19) |
86408 |
Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); screen |
86409 |
Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); titer |
86413 |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) antibody, quantitative |
86769 |
Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] [Coronavirus disease {COVID-19}] testing via multiple-step method |
In-Network Providers and Lab Testing
Network physicians are encouraged, and may be contractually required, to refer our members to participating, in-network providers. Check our online Provider Finder® for labs that are in-network for each member, according to their benefit plan. Referring to in-network providers helps members control their health care costs and avoid balance billing by out-of-network providers.
Claims for COVID-19 Testing- and Antibody-Related Services
Use the following coding process for services that are related to COVID-19 testing or antibody testing.
COVID-19 Diagnosis Codes
To indicate services performed in conjunction with the testing for COVID-19 or COVID-19 antibodies, include one of the following diagnosis codes:
Código |
Descripción |
|---|---|
B34.2 |
Coronavirus infection, unspecified |
B97.29 |
Other coronavirus as the cause of diseases classified elsewhere |
U07.1 |
COVID-19 acute respiratory disease |
Z03.818 |
Encounter for observation for suspected exposure to other biological agents ruled out (possible exposure to COVID-19) |
Z11.52 |
Encounter for screening for COVID-19 |
Z20.822 |
Contact with and (suspected) exposure to COVID-19 |
Z20.828 |
Contact with and suspected exposure to other viral communicable diseases (actual exposure to COVID-19) |
Modifier CS
For services furnished on March 18, 2020, through the end of the PHE, please use the CS modifier on applicable claim lines to identify the service as subject to the cost-sharing waiver for COVID-19. This is for testing-related services that result in an order for or administration of COVID-19 testing or antibody testing. Use the CS modifier only on the codes specified by the Centros de servicios del Programa Medicare y del Programa Medicaid. The following types of claims do not need the CS modifier:
- Screenings before procedures that aren’t related to COVID-19
- COVID-19 tests
- Treatment of COVID-19.
Telemedicina
For information about our 2021 telemedicine coverage see our News & Update article.
Farmacia
We recommend members:
- Keep supplies of their medications on hand and not wait until last-minute to get refills.
- Contact their pharmacies to ask about delivery or curb-side/drive-thru options
- Use their 90-day supply fill benefits (if applies) for non-specialty medications at select retail pharmacies or mail order
Member cost share applies according to their benefit plan. All pharmacy practice safety measures, and prescribing and dispensing laws, remain in force and effect.
Note on Medicare members: Members of these plans can get 90-day fills through mail order:
- Blue Cross Group Medicare Advantage (HMO)SM
- Blue Cross Group Medicare Advantage (PPO)SM
- Blue Cross Group Medicare Advantage Open Access (PPO)SM
- Blue Cross Group MedicareRx (PDP)SM
- Blue Cross Medicare Advantage HMO/HMO SNP
- Blue Cross Medicare Advantage HMO/HMO POS
- Blue Cross Medicare Advantage (PPO)SM
- Blue Cross Medicare Rx (PDP)SM
- Blue Cross Medicare Advantage Dual Care (HMO SNP)SM
Credentialing Process Simplified for COVID-19
BCBSNM is temporarily updating our credentialing policy and processes in response to the COVID-19 emergency. This complies with emergency state and federal regulations and is effective April 3, 2020. The temporary modifications are only in place during the PHE and subject to change based on modifications to state and federal regulations. Thereafter, standard credentialing and processes will apply.
What’s Changing? We are simplifying the process of joining our network.
Subject to state actions on licensing and practice requirements, we will credential providers who meet the following conditions for the duration of the state-declared emergency or as specified by state requirements:
- We will accept practitioners who hold a full unrestricted license to practice granted by any state subject to the state's emergency provider licensure laws. We will accept temporary licenses.
- We will waive accreditation requirements, CMS certification and site visits for institutional providers.
- We will accept expired documents if they have been inactive or expired for less than six-months and the provider is unable to obtain a current document from the issuer due to the COVID-19 emergency. Licenses, accreditations or certifications that have been revoked for cause will not be accepted.
Credentialing criteria and verification sources may change. Please check back often for updates
What is the risk of COVID-19?
According to recent reports from the CDC, the infection rate from COVID-19 is a rapidly evolving situation. The risk assessment may change daily. The latest updates are available on the CDC's Coronavirus Disease 2019 (COVID-19) website. We are ready to help you serve our members and the community in understanding, preventing and potentially treating people who have been affected by COVID-19.
We've developed a member-facing flier about COVID-19 that you may share with your patients.
Más información
Because this is a rapidly evolving situation, you should continue to use Centers for Disease Control guidance on COVID-19, as the CDC has the most up-to-date information and recommendations. In addition, watch for updates on BCBSNM News and Updates.
If you have any questions or if you need additional information, please contact your BCBSNM Provider Relations Representative.
Recursos Relacionados
- COVID-19 FAQs for Medicare Providers
- CARES Act Provider Relief Summary
- COVID-19 Vaccines and Coverage
Al hacer clic en este enlace, irá a un nuevo sitio web o a una aplicación ("sitio"). El sitio al que está por acceder podría ser administrado por un proveedor o un tercero. El sitio también podría proporcionarle información no relacionada con Medicare. Además, algunos sitios podrían solicitarle que acepte sus propios términos de uso y políticas de privacidad.
Indicador de un documento en formato portátil (PDF). Para ver este archivo, es posible que tenga que instalar un programa para leer PDF. La mayoría de los programas para leer documentos en formato PDF se pueden descargar sin costo. Una opción es Adobe® Reader® que cuenta con una función de lector de pantalla. Más detalles y herramientas disponibles en http://access.adobe.com.